The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Tullow Oil meets 2021 guidance; DP Eurasia sales rise

Wed, 26th Jan 2022 17:03

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Tullow Oil PLC - West Africa-focused oil and gas producer - For 2021, working interest oil production averages 59,200 barrels of oil per day, in line with guidance due to growth from the Jubilee field in Ghana and Simba field in Gabon. As a result, in addition to a realised oil price of USD63 per barrel, revenue is expected to be USD1.3 billion, down from USD1.40 billion in 2020. Looking ahead, 2022 production guidance is set between 55,000 to 61,000 barrels per day. However, this guidance will be adjusted following the sale of Occidental Petroleum's interest in Ghana to Kosmos Energy Ltd.

----------

DP Eurasia NV - master franchisee of the Domino's Pizza brand in Turkey, Russia, Azerbaijan and Georgia - For 2021, total systems sales increase 52% year-on-year to TRY2.38 billion, around USD175.4 million, from TRY1.60 billion, driven by strong demand in Turkey and an improved performance in Russia. On a like-for-like basis, system sales growth was 40.6% from 17.4%. Looking ahead, expects adjusted Ebitda for 2021 to be in line with expectations.

----------

Renew Holdings PLC - engineering services provider - For the first quarter ended December 31, performance is in line with management expectations, with order book standing at GBP742 million, up 9.6% from GBP677 million the same date a year before.

----------

Safestyle UK PLC - Bradford, England-based PVCu double-glazed windows provider - For the year ended January 2, underlying posttax profit is set to be ahead of market expectations, on top of revenue to rise 27% year-on-year to GBP143.3 million. Also reflects a 14% rise from the 2019 financial year. Looking ahead, expects operating conditions to improve in 2022.

----------

Real Estate Investors PLC - Midlands focused investment trust - Rent collections levels for 2021 reaches 97.8%, while occupancy at the year-end stood at 85.8%, down from 91.6% the year before.

----------

Ingenta PLC - Oxford, England-based provider of software and services to media - For 2021, expects revenue to remain flat at GBP10.1 million, but adjusted earnings before interest, tax, depreciation and amortisation at GBP1.5 million, up 25% from GBP1.2 million the year before. Will pay a final dividend of 2.0 pence per share for the year.

----------

ECSC Group PLC - Yorkshire, England and Brisbane, Australia-based cyber security services - For 2021, revenue rises 8% to GBP6.1 million from GBP5.7 million the year before, leading to expectations of positive adjusted Ebitda for the period.

----------

Zoo Digital Group PLC - Sheffield, England-based provider of cloud software and media services - For the year ending March 31, revenue is expected to be ahead of market expectations and come to at least USD57 million, a 44% rise from USD39.5 million the year before, driven by new territory launches and the return of new productions. Zoo has become the primary vendor for forthcoming European launch of a global streaming service, which is set to lead to significant orders.

----------

accesso Technology Group PLC - Berkshire, England-based provider of software for leisure, entertainment and cultural sectors - In spite of the effect of the new Omicron variant, for 2021 the company expects revenue be at least USD124 million, ahead of management expectations, and more than doubled from USD56.1 million in 2020. Also reflects a 5.8% rise from USD117.2 million in 2019.

----------

Oakley Capital Investments Ltd - investment trust - As at December 31, net asset value per share is 538 pence, up from 403p the same date a year prior. Over the course of 2021, the trust made GBP137 million in investments, and gained GBP121 million in the share of proceeds.

----------

Bloomsbury Publishing PLC - London-based publisher -For the year ending February 28, expects pretax profit and revenue to be ahead of current market expectations, which is for pretax profit of GBP20.1 million and revenue of GBP197.1 million. For the year prior, pretax profit was GBP17.3 million, and revenue GBP185.1 million.

----------

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Revenue for the six months ended December 31 rises 75% year-on-year to GBP2.2 million from GBP1.2 million, driven by growth in product sales of Alkindi and the initial launch of Efmody in Germany, UK and Austria. Looking ahead, Efmody sales are set to accelerate significantly in the first half of 2022, on expectations of receiving pricing and formulary approvals in its target European markets.

----------

Uniphar PLC - Dublin-based healthcare services firm - Performs in line with expectations for 2021, and expects to report at least an 8% rise in gross profit, driven by a strong performance from all businesses, especially Commercial & Clinical and Product Access.

----------

Gaming Realms PLC - London-based developer and licensor of mobile focused gaming content - For 2021, expects to report a 70% year-on-year increase in adjusted Ebitda to GBP5.6 million, and a 27% rise in revenue to GBP14.5 million, driven mainly by growth from the licensing business, which has launched in two new US iGaming markets of Michigan and Pennsylvania.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
2 Dec 2019 13:19

Diurnal submits application for 'Alkindi Sprinkle' to US FDA

(Sharecast News) - Specialty pharmaceutical company Diurnal Group has submitted a 'New Drug Application' (NDA) to the US Food and Drug Administration (FDA), for the regulatory approval of 'Alkindi Sprinkle', or hydrocortisone granules in capsules for opening, as a replacement therapy of adrenal insufficiency in infants, children and adolescents in the US, it announced on Monday.

Read more
21 Nov 2019 11:36

Diurnal Primary Focus Remains On Progressing Flagship Products

Diurnal Primary Focus Remains On Progressing Flagship Products

Read more
20 Nov 2019 11:36

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

Diurnal To Explore Further Tests As Testosterone Treatment Does Well

Read more
24 Sep 2019 11:21

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

Diurnal Loss Narrows On Research Expenses And Alkindi Launch

Read more
14 Jun 2019 14:26

Diurnal Shareholders Approve Placing, Open Offer Worth GBP6 Million (ALLISS)

(Alliance News) - Pharmaceutical firm Diurnal Group PLC's shareholders on Friday approved its GBP5.9 million fundraise completed earlier in the day.Diurnal, which focuses on patients or

Read more
28 May 2019 13:32

Diurnal Group launches placing and open offer to fund drug development

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced a conditional placing of new ordinary shares in the company and the launch of an open offer on Tuesday, in order to raise funds to progress the development and commercialisation of its products.

Read more
28 May 2019 10:49

Diurnal Raises GBP5 Million Via Placing; Plans GBP1 Million Open Offer (ALLISS)

LONDON (Alliance News) - Diurnal Group PLC said Tuesday it has raised around GBP5.4 million via a 20.6 million share placing priced at 26 pence per share and announced an open offer to raise up to

Read more
10 May 2019 09:36

Polar Capital Global Healthcare Lags Behind Benchmark In First Half

LONDON (Alliance News) - Polar Capital Global Healthcare Trust PLC said on Friday it lagged against its benchmark for the first half of its financial year, as the healthcare trust underperformed a

Read more
24 Apr 2019 15:50

Diurnal gets orphan drug designation for Alkindi in Australia

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that its 'Alkindi' product - hydrocortisone granules in capsules for opening - had been granted orphan drug designation in Australia by the Therapeutic Goods Administration, for the indication 'replacement therapy of adrenal insufficiency (AI) in infants, children and adolescents from birth to 18 years old'.

Read more
24 Apr 2019 10:44

Diurnal Gets Orphan Drug Designation For Alkindi In Australia

LONDON (Alliance News) - Diurnal Group PLC on Wednesday said its adrenal insufficiency drug Alkindi has been granted a second patent and orphan drug designation in Australia.Shares in were

Read more
28 Mar 2019 08:35

Diurnal soars after securing Nordic distribution deal

(Sharecast News) - Diurnal's shares leapt on Thursday despite a widened interim loss as the company landed a marketing and distribution deal for its Alkindi treatment in Scandinavia.

Read more
21 Mar 2019 16:11

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 22 March Sanne GroupFull Year ResultsSmiths GroupHalf Year BootFull Year

Read more
20 Mar 2019 10:33

Diurnal Group upbeat following FDA meeting over 'Alkindi'

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Wednesday that, following a "positive" meeting with the US Food and Drug Administration (FDA), it intended to submit a new drug application (NDA) for 'Alkindi' (hydrocortisone granules in capsules for opening) in the fourth quarter of 2019 as previously planned, with final acceptance of the filing by the FDA expected in 2020.

Read more
25 Feb 2019 10:39

Diurnal expecting Israel launch of 'Alkindi' next year

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Monday that its marketing and distribution partner, Medison Pharma has successfully submitted a market authorisation application (MAA) for its 'Alkindi' (hydrocortisone granules in capsules for opening) product to the Ministry of Health in Israel.

Read more
10 Jan 2019 12:35

Diurnal Granted US Patent But Unsure Why Share Price Has Tripled

LONDON (Alliance News) - Diurnal Group PLC said on Thursday that, aside from the granting of a patent, it is unsure as to why its share price has tripled.Shares were 188% higher on Thursday

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.